**Ardelyx Raises 2025 IBSRELA Revenue Guidance to $270M-$275M as Growth Accelerates**
*October 30, 2025 – 11:08 PM ET*
Ardelyx, Inc. (NASDAQ: ARDX) has updated its revenue guidance for its IBSRELA product, projecting a significant increase for the year 2025. The company now anticipates revenue in the range of $270 million to $275 million, reflecting strong growth momentum.
This upward revision underscores Ardelyx’s confidence in the accelerating demand for IBSRELA and highlights the company’s robust performance in the gastrointestinal therapeutic market.
Investors and stakeholders are encouraged to review the detailed earnings calls and AI-generated insights to better understand the factors driving this positive outlook.
*Stay tuned for further updates as Ardelyx continues to advance its growth strategy in 2025.*
https://seekingalpha.com/news/4512067-ardelyx-raises-2025-ibsrela-revenue-guidance-to-270m-275m-as-growth-accelerates?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news